Abstract:The only available vaccine against pulmonary tuberculosis is Bacille Calmette-Guerin (BCG). As the efficacy reported of the vaccine is not up to the mark, there is an urgent need to develop improved anti-tuberculosis vaccines. Antigen 85B (Ag85B) is a very promising vaccine candidate molecule of Mycobacterium tuberculosis and interferon (IFN)-gamma and has been considered the most attractive correlate of protective immunity. The aim of this study was to construct a novel recombinant BCG (rBCG) to secrete Ag85B and mouse IFN-gamma under control of the Mycobacterial heat shock protein 60 (hsp60) promoter and the antigen signal sequence. Second aim of the present study is to evaluate the immune response in C57BL/6 elicted by the new rBCG. Expression of the fusion protein was readily detectable by western blotting and IFN-gamma bioactivity was detected indirectly by enzyme-linked immunosorbent assay (ELISA). Compared with BCG, rBCG::Ag85B-IFN-gamma was substantially more active in inducing the production of IFN-gamma and tumor necrosis factor (TNF)-alpha from mouse splenocytes. ELISA analysis for IgG, IgG1 and IgG2c showed that rBCG::Ag85B-IFN-gamma induced higher titer of Ag85B and facilitated Th1 type immune response. rBCG::Ag85B-IFN-gamma also improved nitric oxide production levels and enhanced antigen-specific splenocyte proliferation. Moreover, rBCG::Ag85B-IFN-gamma induced human monocytes such as THP-1 cells to enhance expression of CD80, CD86, CD40 and HLA-DR. Flow cytometry analysis confirmed that rBCG::Ag85B-IFN-gamma significantly activated CD4(+) T cells. Assessing combinations of IFN-gamma, TNF-alpha and interleukin-2 at the single-cell level by multiparameter flow cytometry, we found that rBCG::Ag85B-IFN-gamma improved the multifunctional T cells level in comparison to BCG. In conclusion, the present study indicates that rBCG::Ag85B-IFN-gamma increases cell mediated immune response and is a potential candidate vaccine for immunotherapeutic protocols against pulmonary tuberculosis.

Protective Efficacy of a Recombinant BCG Secreting Antigen 85b/rv3425 Fusion Protein Againstmycobacterium Tuberculosisinfection in Mice

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Mouse-Ifn-Gamma Confers Effective Protection Against Mycobacterium Tuberculosis in C57bl/6 Mice

Evaluation of a Recombinant BCG Expressing Antigen Ag85B and PPE Protein Rv3425 from DNA Segment RD11 of Mycobacterium Tuberculosis in C57BL/6 Mice

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

More vaccine efficacy studies on the recombinant bacille calmette-guerin co-expressing Ag85B, Mpt64 190-198 and Mtb8.4

More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4.

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Rv3620c Elicits Specific Th1 Immune Responses in C57bl/6 Mice

Evaluation Of A New Recombinant Bcg Which Contains Mycobacterial Antigen Ag85b-Mpt64(190-198)-Mtb8.4 In C57/Bl6 Mice

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 And Rv2608 Elicits Significantly Enhanced Cellular Immune And Antibody Responses In C57bl/6 Mice

Recombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

Recombinant BCG vaccine expressing multistage antigens of Mycobacterium tuberculosis provides long-term immunity against tuberculosis in BALB/c mice

Immunogenicity Analysis of a Recombinant BCG Vaccine Strain Overexpressing Rv3478 Protein

Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-α induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice: Recombinant BCG expressing Ag85B-ESAT-6-TNF-α

Dose of Incorporated Immunodominant Antigen in Recombinant BCG Impacts Modestly on Th1 Immune Response and Protective Efficiency Against Mycobacterium Tuberculosis in Mice

Heterologous Boosting With Listeria -Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection.

Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.

A multistage protein subunit vaccine as BCG-booster confers protection against Mycobacterium tuberculosis infection in murine models

Heterologous Boosting With<i>Listeria</i>-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection

Recombinant BCG Prime and PPE Protein Boost Provides Potent Protection Against Acute Mycobacterium Tuberculosis Infection in Mice

A Multistage Protein Subunit Vaccine As Bcg-Booster Confers Protection Against M Ycobacterium Tuberculosis Infection in Murine Models

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice